Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1973 • 12,522 citations

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

2004 • 1,111 citations

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

2000 • 1,079 citations

A Meta-analysis of the Efficacy of Second-Generation Antipsychotics

2003 • 1,008 citations

Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology

2003 • 918 citations

Atypical Antipsychotics: Mechanism of Action

2002 • 892 citations

Serotonin receptors : their key role in drugs to treat schizophrenia

2003 • 759 citations

Do Novel Antipsychotics Have Similar Pharmacological Characteristics? A Review of the Evidence

1998 • 719 citations

Neuropsychopharmacology

2004 • 652 citations

Binding of antipsychotic drugs to human brain receptors

2000 • 594 citations

Functional, molecular and pharmacological advances in 5-HT receptor research

2004 • 325 citations

5-ht6 Receptors

2004 • 296 citations

Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders

2003 • 250 citations

Dopamine D3 receptor antagonists as therapeutic agents

2005 • 233 citations

Genetic knockout and pharmacological blockade studies of the 5-HT7 receptor suggest therapeutic potential in depression

2005 • 224 citations

Serotonergic basis of antipsychotic drug effects in schizophrenia

1998 • 206 citations

Possible implications of the dopamine D3 receptor in schizophrenia and in antipsychotic drug actions

2000 • 194 citations

5-HT7 Receptors

2004 • 181 citations

Efficacy and Tolerability of Asenapine in Acute Schizophrenia

2007 • 173 citations

Contributions of 5-HT2C receptors to multiple actions of central serotonin systems

2004 • 171 citations

Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response

2004 • 132 citations

A Comparative Review of New Antipsychotics

1999 • 132 citations

α-Adrenoceptor modulation hypothesis of antipsychotic atypicality

2003 • 132 citations

Inhibitory Effects of Antipsychotics on Carbachol-Enhanced Insulin Secretion From Perifused Rat Islets

2005 • 128 citations

Current and Novel Approaches to the Drug Treatment of Schizophrenia

2001 • 126 citations

Management of the Negative Symptoms of Schizophrenia

2003 • 125 citations

Metabolic risk during antipsychotic treatment

2004 • 123 citations

Predictive value of cognition for different domains of outcome in recent-onset schizophrenia

2006 • 98 citations

Understanding antipsychotic "atypicality": a clinical and pharmacological moving target.

2003 • 93 citations

Safety of Available Agents Used to Treat Bipolar Disorder

2003 • 84 citations

Atypical antipsychotic drug actions: unitary or multiple mechanisms for ‘atypicality’?

2003 • 81 citations

Combined α2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat

2005 • 80 citations

Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology

2003 • 73 citations

Long‐term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome

2000 • 71 citations

Quality of life and functioning ability in subjects vulnerable to psychosis

2007 • 67 citations

Cognition, schizophrénie et effet des antipsychotiques : le point de vue d’un laboratoire de recherche clinique

2006 • 65 citations

Pharmacogenetic studies of response to risperidone and other newer atypical antipsychotics

2005 • 50 citations

Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits

2004 • 24 citations

Pharmacological treatment strategies for schizophrenia

2004 • 20 citations

Dopamine and glutamate dysfunctions in schizophrenia: Role of the dopamine D3 receptor

2004 • 20 citations

Org-5222

1993 • 11 citations

Predicting Clinical Antipsychotic Doses from Preclinical and PET studies: A Case Study with Asenapine

2003 • 1 citations